Today I wrote about the issue of genetic testing and warfarin management. And now here is a new article focusing on personalized therapy in lung cancer. Adi F. Gazdar published his thoughts in the New England Journal of Medicine.
Successful examples of targeted therapy include imatinib for the treatment of BCR-ABL–positive chronic myeloid leukemia and the reversible tyrosine kinase inhibitors, erlotinib and gefitinib, for blocking the gene that encodes epidermal growth factor receptor (EGFR) in subgroups of patients with non–small-cell lung cancer.
Overall, the rate of survival of patients carrying an EGFR mutation who were treated with the tyrosine kinase inhibitor was relatively high, as compared with that of historical control subjects who were treated with chemotherapy.
We should be prepared for a lot of similar examples in different fields of medicine in the next few years.